Member Info for PCS1954

Good morning stevej,

Thanks for your follow up which had more clarity than the one I received for a similar question!!

I think as a bb, we’ve probably now conjectured on every outcome both scientifically and financially, time to wait for the BoD to make their comments ( which may not be immediate ) and hopefully, it’s what we all hoped for!

Have a good Sunday!

GLA

As I’ve said previously, I’m no expert but below is answer I received via AI that maybe of help to understand our Toxicity Studies:-

In a 16-week toxicity study, daily dosing typically ceases on Day 112 (exactly 16 weeks × 7 days), marking the end of the exposure phase.

Immediately following this, animals either undergo terminal necropsy or enter a designated treatment-free recovery period.

What Happens After Dosing Ceases?The subsequent steps are dictated by whether the subjects are in the Main Study Group or a Satellite/Recovery Group (usually included per regulatory standards like ⁠OECD Guidelines for Testing of Chemicals).

1. Main Study Group (Terminal Necropsy)Immediate Euthanasia: Animals are typically humanely euthanized within 24 to 48 hours following the final dose on Day 112.

Comprehensive Evaluation: Technicians conduct gross necropsies, organ weighing, and extensive tissue collection to evaluate the systemic toxicity and target-organ damage of prolonged exposure.

Histopathology: Tissues are preserved, sectioned, and examined microscopically for lesions or cellular abnormalities.

2. Satellite Group (Recovery Phase)Drug Clearance Window: If a recovery group is included (e.g., to see if adverse effects are reversible), dosing stops on Day 112 but the animals are kept alive for a treatment-free observation window.Duration: This window generally lasts 14 to 28 days. For biologics or compounds with long half-lives, it can extend up to 8 to 12 weeks to ensure the drug completely clears the system.

Delayed Terminal Procedures: Only after this specified recovery period concludes are these animals euthanized and subjected to the same necropsy and histopathology to measure the persistence of—or recovery from—toxic effects.

Hope it’s of interest

GLA

Hi Bb1

It’s always been my belief that we were “advised” came with a potential financial “incentive” as the business cash flow doesn’t add up and maybe SRA737 was to be the cash injection - as you say who knows, but fingers crossed.

My worry - the MHRA debacle and the loss of a raise due to such ultimately led us to RF, so there is history of not being prepared for a rainy day!!

As I’ve previously stated, I feel there is a very cautious and understated approach of information provided to shareholders by the BoD over the last year or so - hopefully, a lesson learnt and the next month or so some positive “enlightenment” on both the science and financial fronts!

Not sure we can say much more, just wait and hope that we “backed a good ‘un”!!

GLA

Fortunately, I took a reasonable chunk out in 2021 after originally investing in Dec 2009 and building up to a 33m holding, still have in my world a decent holding but next 6 months something in value has to happen as even 10p WRAP holders will start getting fidgety!

Hopefully, dosing successfully finished and SP cuts the “cryptic” monologue and we start pushing some decent RNS’s out to give the often alluded to “shareholder value” to all holders old and new 🤞

Enjoy your weekend to All

GLA

Worth remembering that we’re three tiers of shareholders - pre WRAP, Wrap and some a mix of both - the sudden surge over the last 3 working days represents 100/150% return for WRAP tier, doesn’t surprise me if they wish to take some profits and I still think the 270k yesterday was someone unexpectedly caught by a stop loss by a sharp MM.

Ultimately an innocuous CC caused a “spike” which has been taken advantage of - hopefully, we are in week 16 and dosing completes successfully in the next few days and the next phase in the “studies” gets underway and the “real” news starts to emerge on all fronts in a good way 🤞

GLA

Given the buys yesterday, and continued “trading today - someone may have unfortunately got caught in a “stop loss” by the MM’s and may even be trying to retrieve as we all “speculate” - many permutations are imaginable including taking a profit, need to go with what you think!

GLA

Hi Krone & stevej

Hopefully, June is the month where the old “London Bus” adage comes into play and time for both progressive and positive RNS’s to get released on our “growing” pipeline, interesting, no mention of SRA737 in “CC” and coming up for 15 months of majority ownership!

Bio San Diego is listed on our website, if we are attending with our American “business development friends”, hopefully, it’s with real purpose and “CC” becomes “Contract Completed” and not another “Chit Chat”!

A good week for the sp, long may it continue in the upward trend 🤞

GLA

The 11m warrants at 12.5p would also bring in £1.4m to the coffers for less than 10% dilution, maybe part of the BoD’s “projected income”?

The one thing that has struck me, is there is no “noise” from the BoD, remember “orderly queue”, “definitely in the shop window” etc - everything appears low key as if following a very specific process/pathway.

All being well, I would think we commence week 16 tomorrow and as of Monday the HNWI’s original warrants would have expired - June is building into potentially an exciting month 🤞

GLA

With you on that potnak, some clever reflective dialogue from SP that didn’t actually say anything- because he can’t say anything on our two lead compounds maybe ? 🤞

GLA

Morning

https://endpoints.news/asco26-cancer-immunotherapys-magic-bullet-era-is-fading-heres-whats-next/

What better time for Sareum to step forth with SRA737 and SDC-1802 and offer a way of filling the vacuum void. 🤔

GLA

Hi HBD, don’t shoot the messenger 😂

Seriously, we ‘re simply at crunch time imo, hopefully, a good practical dosing phase, some quality analysis and hopefully some very good business acumen to get that elusive “shareholder value”.

Many contribute on here, take the extremities away and all said and done we’re fortunate to be left with a collection of posts ( may not always agree from time to time ) leading to a balanced overview imo - easy for us to criticise, myself included - but, hopefully we’re edging closer 🤞

Time for beer number 2, enjoy evening to all.

GLA

Hi HBD,

Seem to recall SP once saying it would be nice to “announce” peer review at a attended conference - June Bio approaching, hopefully Toxicity Studies dosing concluded and moving into the full analysis period - a “perfick” sales pitch, if one is needed.

Selfishly, I’m still wishfully thinking we’re being “guided” and some monetary value kicks in🤞

Then again, I’ve been in the sea and sun all day 🥵

GLA

Morning stevej & desamax

Hopefully, a Chairman’s Corner this week and an indication of the progress we’re making - in theory, the 16 week study has certain pinch points that would have been forwarded to JR and TM to review.

Whilst, not a total update SP’s “CC” report should hopefully give an indication of how the BoD are “driving” us into H2 on both the science and financial fronts - we must be reaching a stage where “cryptic” messages are meeting their “sell by date”, especially, in the case of SRA737 🤞

Enjoy the 🌞

GLA

Hopefully, no time to read IR as concentrating on a “deal” 🤞

GLA

Totally agree, we really are at the “crunch time”, think SP will continue with the “understated” approach until he can announce factual news.

You need to dig up some more “ script” for him 😉

Have a good weekend!

GLA

Sorry HBD, just seen your post as I posted- I’d go along with that!

GLA

Hi Elcap

Given RNS of 17th Feb stated we had restarted, should be 14 weeks to date - 87.5% completed, 🤞hopefully, all going well for the forthcoming analysis observations.

Not sure the thread title suits the post!

GLA

Hi Aber

Think I go back far enough not to have an agenda other than hopefully get a decent return on my investment.

I have the balance of my holding with no intention of adding as my exit strategy if it comes off will be enough for what I want in my life.

However, I do look at the various inflection points in getting to that exit and the expiry of the HNWI’s is one - in theory - a positive of less dilution, negative a loss of income to the company.

I certainly wasn’t advocating an “agenda” when mentioning the possibility of a chat and say compensation deal - more utilising a situation to give us a stronger financial position now.

I haven’t mentioned the “f” word, stated I have no intention of buying any more shares -so no agenda here, just a realistic discussion point on a public bb.

Of course, a “deal” on SRA737 over the next month or 2 ceases the discussion, but, do we have a guarantee of that? I’m not sure!

Back to the Cornish sunshine.

GLA

I think I’ve made my hope clear on how we go forward with finances, however, there are no guarantees- so you should consider the options.

For me, the BoD statement of “sufficient” funds in the interim results is riddled with ambiguity “we consider”, “projected income” etc.. and “necessary savings”, what are we wasting money on to enable that given the committed pathway - the only option I see is withheld salaries, doesn’t exactly put you in a strong negotiating position with the other side of the table when pushing for a deal - “Dr. Parker it’s not what it’s worth- it’s what you can’t afford to turn down”

At the end of the month, there is almost certainly going to be a reduction in our potential dilution, I wouldn’t be surprised if it is used, and who knows a reasonable sum of income to the current scenario may actually give confidence for a small sp rise as the stated pathway continues.

Nothing written in stone, just in our DNA as drug development company and a consideration - let’s not beat ourselves up over it.

Enjoy your day, weather looking good.

GLA

Hi Seawolf, I was not suggesting for the HNWI to invest, merely like potnak, I work on our share circulation to include potential warrants and once their warrants expire a raise would possibly keep the status quo and therefore my exit strategy calculations held.

Mind you, if I was a HNWI, and I’m not - but, interested in Sareum’s aims - perhaps, by way of “compensation” on expiry of my warrants which would coincide virtually with completion of the 16 week dosing period, a little “chat” with the BoD for some ex gratia issue of shares for a “suitable” investment of funds to continue along the stated pathway - no one’s really out of pocket as the warrants originally would have expected to be exercised for further funds!

The world of finance is as complex as the laboratory itself.

GLA